Wolfe Research analyst Tim Anderson upgraded Merck to Outperform from Peer Perform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Merck provides update on Phase 3 MOVe-AHEAD trial evaluating LAGEVRIO
- Merck: FDA accepts for priority review sNDAs for PREVYMIS
- Merck announces sale of campus in Kenilworth, N.J.
- Merck’s Keytruda with chemotherapy shows improvements in Phase 3 trial
- AstraZeneca, Merck present final results from Phase III PROpel trial